Sign up
Pharma Capital

VentriPoint Diagnostics brings in over C$1mln from placing; closes second tranche

The group issued around 2.43mln units at C$0.21 each for gross proceeds of $511,499.94
1536934697_MedicalMonitor.jpg
VentriPoint has developed a suite of applications for all major heart diseases and imaging modalities

Heart-imaging specialist VentriPoint Diagnostics Ltd (CVE:VPT) has closed the second and final tranche of its previously announced placing, raising more than C$511,000.

The group issued around 2.43mln units at C$0.21 each for gross proceeds of $511,499.94. In total, the firm raised gross proceeds of C$1,011,499.94 under the placing.

Proceeds will be used for sales and marketing, development and general working capital, Ventripoint said. Each unit consists of one Ventripoint share, and one-half of a share warrant. Each whole warrant will entitle the bearer to buy one further share at US$0.34 each for two years after the issue.

Chief executive Dr George Adams subscribed for 1.5mln units, the company said in the regulatory filing.

Giles_55af4ddca6481.jpg
Why Invest In VentriPoint Diagnostics Ltd.? Read More Here

Register here to be notified of future VPT Company articles
View full VPT profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.